Press Releases

Endonovo Therapeutics Changes Ticker Symbol to ENDV

Download PDF

LOS ANGELES, CA -- (Marketwired) -- 05/05/14 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), formerly Hanover Portfolio Acquisitions, Inc. (OTCQB: HVPA), a biotechnology company developing bioelectronic and cell based therapies, announced today that the Company is now trading under the new symbol ENDV, effective May 5, 2014. The change is in accordance with the exchange's recognition of the Company's name change outlined in the 8K filed January 24, 2014. All stock trading, filings and market related information will be traded under the new ticker symbol ENDV.

Additionally, the Company's common stock will trade under a new CUSIP number (29272H102).

"It is exciting to near the end of this phase of our corporate evolution by trading under our new ticker symbol, which more accurately reflects our new direction in biotechnology," said Endonovo Therapeutics CEO, Alan Collier. "The symbol change allows us to begin aligning our corporate image with our growing brand. We have made a tremendous amount of progress this year in completely changing the Company's strategic direction and creating shareholder value by acquiring and developing innovative intellectual property in the biotechnology space."

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a publicly traded biotechnology company developing novel cell-based therapies and non-invasive bioelectronic therapies designed to extend and enhance the human life by regenerating tissues and organs that have become injured or damaged due to disease and age. The Company is developing therapies for various inflammatory, autoimmune and degenerative diseases using cell therapies and Time-Varying Electromagnetic Fields (TVEMF).

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investor Relations Contact:

Mr. Ramiro Contreras
Vice President of Corporate Development
Endonovo Therapeutics, Inc.

Source: Endonovo Therapeutics, Inc.